检索结果-南通市图书馆

Nomograms for colorectal cancer:A systematic review

World Journal of Gastroenterology 2015年第41期21卷 11877-11886页

作者： Kazushige Kawai Eiji Sunami Hironori Yamaguchi Soichiro Ishihara Shinsuke Kazama hiroaki nozawa Keisuke Hata Tomomichi Kiyomatsu Junichiro Tanaka Toshiaki Tanaka Takeshi Nishikawa Joji Kitayama Toshiaki Watanabe Department of Surgical Oncology Graduate School of Medicinethe University of Tokyo

AIM: To assist in the selection of suitable nomograms for obtaining desired predictions in daily ***: We conducted electronic searches for journal articles on colorectal cancer(CRC)-associated nomograms using the search terms colon/rectal/colorectal/nomogram. Of 174 articles initially found, we retrieved 28 studies in which a nomogram for CRC was ***: We discuss the currently available CRCassociated nomograms, including those that predict the oncological prognosis, the short-term outcome of treatments, such as surgery or neoadjuvant chemoradiotherapy, and the future development of CRC. Developing nomograms always presents a dilemma. On the one hand, the desire to cover as wide a patient range as possible tends to produce nomograms that are too complex and yet have C-indexes that are not sufficiently high. Conversely, confining the target patients might impair the clinical applicability of constructed ***: The information provided in this review should be of use in selecting a nomogram suitable for obtaining desired predictions in daily clinical practice.

关键词： Colon Rectum Nomograms Prognosis Cancer

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Breakthrough therapy for peritoneal carcinomatosis of gastric cancer:Intraperitoneal chemotherapy with taxanes

引用

World Journal of Gastrointestinal Oncology 2015年第11期7卷 285-291页

作者： Hironori Yamaguchi Joji Kitayama Hironori Ishigami Shinsuke Kazama hiroaki nozawa Kazushige Kawai Keisuke Hata Tomomichi Kiyomatsu Toshiaki Tanaka Junichiro Tanaka Takeshi Nishikawa Kensuke Otani Koji Yasuda Soichiro Ishihara Eiji Sunami Toshiaki Watanabe Department of Surgical Oncology the University of Tokyo

The effect of chemotherapy on peritoneal carcinomatosis(PC) of gastric cancer remains ***,the intraperitoneal(IP) administration of taxanes [e.g.,paclitaxel(PTX) and docetaxel(DOC)] during the perioperative period has shown promising ***,we summarized the rationale and methodology for using IP chemotherapy with taxanes and reviewed the clinical *** administered taxanes remain in the IP space at an extremely high concentration for 48-72 *** drug directly infiltrates peritoneal metastatic nodules from the surface and then produces antitumor effects,making it ideal for IP *** are two types of perioperative IP chemotherapy with taxanes: neoadjuvant intraperitoneal and systemic chemotherapy and sequential perioperative intraperitoneal chemotherapy(SPIC).In SPIC,patients receive neoadjuvant IP chemotherapy and the same regimen of IP chemotherapy after cytoreductive surgery(CRS) until disease ***,a taxane dissolved in 500-1000 m L of saline at ordinary temperature is administered through an IP access port on an outpatient *** to phase Ⅰ?studies,the recommended doses(RD) are as follows: IP DOC,45-60 mg/m2; IP PTX [without intravenous(IV) PTX],80 mg/m2; and IP PTX(with IV PTX),20 mg/*** Ⅱ studies have reported a median survival time of 14.4-24.6 mo with a 1-year overall survival of 67%-78%.A phase Ⅲ study comparing S-1 in combination with IP and IV PTX to S-1 with IV cisplatin started in *** prognosis of patients who underwent CRS was better than that of those who did not; however,this was partly due to selection *** several phase Ⅱ studies have shown promising results,a randomized controlled study is needed to validate the effectiveness of IP chemotherapy with taxanes for PC of gastric cancer.

关键词： Taxane Paclitaxel Docetaxel Carcinoma Gastric canc

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Study protocol of the Asian XELIRI ProjecT(AXEPT):a multinational,randomized,non-inferiority,phase Ⅲ trial of second-line chemotherapy for metastatic colorectal cancer, comparing the eicacy and safety of XELIRI with or without bevacizumab versus FOLFIRI w

引用

Chinese Journal of Cancer 2016年第12期35卷 735-742页

作者： Masahito Kotaka Ruihua Xu Kei Muro Young Suk Park Satoshi Morita Satoru Iwasa Hiroyuki Uetake Tomohiro Nishina hiroaki nozawa Hiroshi Matsumoto Kentaro Yamazaki Sae-Won Han Wei Wang Joong Bae Ahn Yanhong Deng Sang-Hee Cho Yi Ba Keun-Wook Lee Tao Zhang Taroh Satoh Marc E.Buyse Baek-Yeol Ryoo Lin Shen Junichi Sakamoto Tae Won Kim Gastrointestinal Cancer Center Sano HospitalHyogo 655-0031Japan. State Key Laboratory of Oncology in South China Department of Medical OncologyCollaborative Innovation Center for Cancer MedicineSun Yat-sen Univer-sity Cancer CenterGuangzhouGuangdong 510060P.R.China. Depart-ment of Clinical Oncology Aichi Cancer Center HospitalNagoya 464-8681Japan. Department of Medicine Samsung Medical CenterSungkyunkwan University School of MedicineSeoul 135-710South Korea. Department of Biomedical Statistics and Bioinformatics Graduate School of MedicineKyoto UniversityKyoto 606-8501Japan. Gastrointestinal Medical Oncology Division National Cancer Center HospitalTokyo 104-0045Japan. Depart-ment of Surgical Specialties Graduate SchoolTokyo Medical and Dental UniversityTokyo 113-8519Japan. Department of Gastrointestinal Medical Oncology National Hospital Organization Shikoku Cancer CenterMatsuy-ama 791-0280Japan. Department of Surgical Oncology The University of TokyoTokyo 113-0033Japan. Department of Surgery Tokyo Metropoli-tan Komagome HospitalTokyo 113-8677Japan. Division of Gastrointestinal Oncology Shizuoka Cancer CenterShizuoka 411-8777Japan. Department of Internal Medicine Seoul National University HospitalSeoul 110-744South Korea. Department of Gastrointestinal Oncology The First People's Hospital of FoshanFoshanGuangdong 528000P.R.China. Department of Inter-nal Medicine Yonsei University College of MedicineSeoul 120-752South Korea. Department of Medical Oncology The Sixth Ailiated HospitalSun Yat-sen UniversityGuangzhouGuangdong 510655P.R.China. Depart-ment of Hematology-Oncology Chonnam National University Medical SchoolGwangju 519-809South Korea. Department of Digestive Oncology Tianjin Medical University Cancer Institute and HospitalTianjin 300060P.R.China. Department of Internal Medicine Seoul National University Bundang Hos-pitalSeoul National University College of MedicineSeongnam 463-707South Korea. Department of Medical Oncology Union Hospital of Tongji Medical College

Background: Capecitabine and irinotecan combination therapy(XELIRI) has been examined at various dose levels to treat metastatic colorectal cancer(m CRC). Recently, in the Association of Medical Oncology of the German Cancer Society(AIO) 0604 trial, tri?weekly XELIRI plus bevacizumab, with reduced doses of irinotecan(200 mg/m^2 on day 1) and capecitabine(1600 mg/m^2 on days 1–14), repeated every 3 weeks, has shown favorable tolerability and eicacy which were comparable to those of capecitabine and oxaliplatin(XELOX) plus bevacizumab. The doses of capecit?abine and irinotecan in the AIO trial are considered optimal. In a phase I/II study, XELIRI plus bevacizumab(BIX) as second?line chemotherapy was well tolerated and had promising eicacy in Japanese ***: The Asian XELIRI Projec T(AXEPT) is an East Asian collaborative, open?labelled, randomized, phase Ⅲ clinical trial which was designed to demonstrate the non?inferiority of XELIRI with or without bevacizumab versus standard FOLFIRI(5?fluorouracil, leucovorin, and irinotecan combination) with or without bevacizumab as second?line chemo?therapy for patients with m CRC. Patients with 20 years of age or older, histologically conirmed m CRC, Eastern Coop?erative Oncology Group performance status 0–2, adequate organ function, and disease progression or intolerance of the irst?line regimen will be eligible. Patients will be randomized(1:1) to receive standard FOLFIRI with or with?out bevacizumab(5 mg/kg on day 1), repeated every 2 weeks(FOLIRI arm) or XELIRI with or without bevacizumab(7.5 mg/kg on day 1), repeated every 3 weeks(XELIRI arm). A total of 464 events were estimated as necessary to show non?inferiority with a power of 80% at a one?sided α of 0.025, requiring a target sample size of 600 patients. The 95% conidence interval(CI) upper limit of the hazard ratio was pre?speciied as less than ***: The Asian XELIRI Projec T is a multinational phase III trial being conducted to provide evidence fo

关键词： Metastatic colorectal cancer Randomized phase Ⅲ clinical trial XELIRI Bevacizumab Second-line therapy

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

颈缘线处理中邻间隙龈中点线概念的引入

引用

中国口腔医学继续教育杂志 2010年第6期13卷 37-50页

作者： Takeshi nozawa Shunzo Tsurumaki Satoshi Yamaguchi hiroaki Enomoto Koichi Lto 王宪娥（译）徐莉（审）不详北京大学口腔医学院牙周科北京海淀区中关村南大街22号100081

本文的第一个目的是研究上颌前牙区龈缘最低点与邻间隙龈中点（IGM）线的关系。在观察的77位病人模型上标记出牙颈缘最低点及近、远中邻间隙的龈中点后，在硅橡胶模型上测量出连接邻间隙龈中点的IGM线到颈缘最低点的最短距离。结果显示... 详细信息

本文的第一个目的是研究上颌前牙区龈缘最低点与邻间隙龈中点（IGM）线的关系。在观察的77位病人模型上标记出牙颈缘最低点及近、远中邻间隙的龈中点后，在硅橡胶模型上测量出连接邻间隙龈中点的IGM线到颈缘最低点的最短距离。结果显示上颌中切牙颈缘最低点的平均位置与IGM线一致。在上颌侧切牙，颈缘的最低点在IGM线腭侧0．24mm．而在尖牙则位于唇侧03mm。本研究的第二个目的是通过一些病例于颈缘线处理中．IGM线概念的引入。一位牙龈厚平生物型的患者．采用临床牙冠延长手术治疗，经过对牙龈冠向生长情况的长时间观察，发现颈缘最低点最终与IGM线接近。而对一个薄扇牙龈生物型的病例短期观察中，发现邻间隙牙龈增加后游离龈也会增加。在一个Miller I度牙龈退缩的病例中．基于IGM线的概念，进行了一个冠向复位瓣联合转瓣技术的手术。根据本研究及临床病例观察得到的结果，IGM线有可能成为牙周成形手术中颈缘线处理的参照标准。

关键词：颈缘线牙龈退缩上颌前牙区病例观察手术治疗 IGM 上颌侧切牙最短距离

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：